doxorubicin hydrochloride

P2, N=23, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed

P3, N=177, Active, not recruiting, University of Arkansas | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027

Here, we employed an integrative biochemical approach combining a novel flux tracing method (using d17dihydrosphingosine) with in situ enzymatic activity assays in the context of treatment with Doxorubicin (Dox), a DNA-damaging agent causing well-established dose-dependent activation of p53...iv) With respect to inhibition of d17sphingomyelin synthesis, an investigation into ceramide transport to the Golgi identified the ceramide transport protein 1 (CERT1) as a novel target of Dox (reduction of protein and activity) and p53 (reduction of activity, particularly at low Dox). These observations underscore p53's prominent role as a master regulator of SPL metabolism, inducing major remodeling of cellular SPL metabolism with extensive and integrated effects on sphingolipid synthesis.

The most promising salvage options for patients responding insufficiently to treatment are the chemotherapy combinations, topotecan/vincristine/doxorubicin (TVD), topotecan/cyclophosphamide/etoposide (TCE), ifosfamide/carboplatin/etoposide (ICE) or topotecan/cyclophosphamide (TopoCy), or [131I]-mIBG therapy. Early-phase clinical trials are also a possible option in this setting.

P2, N=23, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Apr 2026

Among them, HB183, HB209, and HB210 exhibited the most potent growth inhibition (GI) activity, with average values of 78.25%, 76.34%, and 79.14%, respectively-surpassing the reference drug doxorubicin (61.89%)...Molecular docking, molecular dynamics simulation (for 500 ns), and MM-GBSA calculations for the lead analogue (HB183) towards the BCL-2 target, as a crucial one in the pathway of apoptosis induction, were performed to support the mechanistic investigation. These findings suggest that HB183 is a promising lead for further development as a selective and potent anticancer agent, particularly in the treatment of breast cancer.

Postoperatively, the patient received adjuvant chemotherapy with the AIM (doxorubicin, ifosfamide, and mesna) regimen. Given the extreme rarity of PRSS, we discuss the diagnostic challenges, molecular characteristics, and treatment approach adopted at our institution, contributing to the limited but growing body of knowledge on this rare entity.

Herein, dose- and time-dependent in vitro anticancer activity studies of anti-inflammatory drugs, including celecoxib (C), indomethacin (I), and meloxicam (M), in combination with natural products (taxifolin (T), quercetin (Q), and rutin (R)) and doxorubicin (Dox), were carried out in MDA-MB-231, BT-20, MCF-7, and HT-29 human cancer cell lines. The obtained results highlight that drug C and T may be potential inhibitor candidates as SphK1 inhibitors for targeted cancer therapy. Overall, the combination of drug C with T has shown promising results, anticancer effects in breast and colon cancer cells and antiulcerative effects in rats.

P3, N=662, Active, not recruiting, University of Heidelberg Medical Center | Trial completion date: Mar 2027 --> Jun 2028 | Trial primary completion date: May 2025 --> Jun 2028

P=N/A, N=202, Not yet recruiting, Shanghai Zhongshan Hospital

Several compounds, particularly 6f and 6h-j, demonstrated potent cytotoxicity, with IC50 values as low as 4.82-10.23 µM against MCF-7 cells, surpassing reference drugs like sorafenib and doxorubicin. In silico studies indicated strong binding interactions of the compounds with kinases, and pharmacokinetic assessments revealed favorable properties. These findings underscore the potential of benzimidazole-hydrazone derivatives as effective cancer therapeutics, meriting further investigation into their mechanisms and clinical implications.

Notably, overexpression of IGFL2-AS1 in HeLa cells significantly reduced cell proliferation, migration, clonogenic survival, and enhanced sensitivity to cisplatin and doxorubicin. Conversely, IGFL2-AS1 repression in SiHa cells yielded no significant phenotypic changes, suggesting a context-dependent mechanism. IGFL2-AS1 is identified as a histological subtype-specific prognostic biomarker and promising therapeutic target for cervical adenocarcinoma.